Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) EBITDA Margin: 2010-2021

Historic EBITDA Margin for Neurocrine Biosciences (NBIX) over the last 9 years, with Sep 2021 value amounting to 7.50%.

  • Neurocrine Biosciences' EBITDA Margin rose 3032.00% to 7.50% in Q3 2021 from the same period last year, while for Sep 2021 it was 3.41%, marking a year-over-year decrease of 570.00%. This contributed to the annual value of 5.12% for FY2019, which is 46.00% up from last year.
  • According to the latest figures from Q3 2021, Neurocrine Biosciences' EBITDA Margin is 7.50%, which was down 48.41% from 14.54% recorded in Q2 2021.
  • Over the past 5 years, Neurocrine Biosciences' EBITDA Margin peaked at 33.95% during Q3 2018, and registered a low of -954.43% during Q2 2017.
  • In the last 3 years, Neurocrine Biosciences' EBITDA Margin had a median value of 14.18% in 2019 and averaged 4.97%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first skyrocketed by 94,924bps in 2018, then plummeted by 4,750bps in 2020.
  • Over the past 5 years, Neurocrine Biosciences' EBITDA Margin (Quarterly) stood at 5.90% in 2017, then surged by 794bps to 13.84% in 2018, then fell by 1bps to 13.83% in 2019, then tumbled by 4,750bps to -22.82% in 2020, then spiked by 3,032bps to 7.50% in 2021.
  • Its last three reported values are 7.50% in Q3 2021, 14.54% for Q2 2021, and 13.23% during Q1 2021.